Literature DB >> 4924999

In vitro studies of alpha-carboxyl-3-thienylmethyl penicillin, a new semisynthetic penicillin.

G P Bodey, B Deerhake.   

Abstract

The activity of a new semisynthetic penicillin, alpha-carboxyl-3-thienylmethyl penicillin (BRL-2288) was determined against 535 clinical isolates of gram-negative bacilli, by using the tube dilution technique. Nearly 80% of isolates of Proteus spp. were inhibited by 3.12 mug or less of this antibiotic per ml. BRL-2288 was as active as ampicillin against Escherichia coli. It was slightly more active than carbenicillin or 6-(d-alpha-sulfoaminophenylacetamido)-penicillanic acid against Pseudomonas sp., with over half of the isolates being inhibited by 50 mug or less of BRL-2288 per ml. Isolates of Klebsiella sp. were routinely resistant to this antibiotic. The drug was bactericidal against most sensitive organisms. BRL-2288 was less active against large inocula. A strain of Pseudomonas sp. which developed resistance to carbenicillin also developed resistance to BRL-2288 simultaneously.

Entities:  

Mesh:

Substances:

Year:  1971        PMID: 4924999      PMCID: PMC377117          DOI: 10.1128/am.21.1.61-65.1971

Source DB:  PubMed          Journal:  Appl Microbiol        ISSN: 0003-6919


  20 in total

1.  CAUSES OF DEATH IN ACUTE LEUKEMIA: A TEN-YEAR STUDY OF 414 PATIENTS FROM 1954-1963.

Authors:  E M HERSH; G P BODEY; B A NIES; E J FREIREICH
Journal:  JAMA       Date:  1965-07-12       Impact factor: 56.272

2.  Clinical and laboratory studies with carbenicillin. A new penicillin active against Pseudomonas pyocyanea.

Authors:  W Brumfitt; A Percival; D A Leigh
Journal:  Lancet       Date:  1967-06-17       Impact factor: 79.321

3.  Resistance of Pseudomonas aeruginosa to carbenicillin.

Authors:  S M Bell; D D Smith
Journal:  Lancet       Date:  1969-04-12       Impact factor: 79.321

4.  The importance of underlying disease in patients with gram-negative bacteremia.

Authors:  M A Freid; K L Vosti
Journal:  Arch Intern Med       Date:  1968-05

5.  The treatment of infections due to Pseudomonas aeruginosa with carbenicillin ("Pyopen").

Authors:  B C Stratford
Journal:  Med J Aust       Date:  1968-11-16       Impact factor: 7.738

6.  Carbenicillin therapy of gram-negative bacilli infections.

Authors:  G P Bodey; V Rodriguez; J K Luce
Journal:  Am J Med Sci       Date:  1969-06       Impact factor: 2.378

7.  New semi-synthetic penicillin active against Pseudomonas pyocyanea.

Authors:  P Acred; D M Brown; E T Knudsen; G N Rolinson; R Sutherland
Journal:  Nature       Date:  1967-07-01       Impact factor: 49.962

8.  Gram-negative septicemia: a growing threat.

Authors:  W A Altemeier; J C Todd; W W Inge
Journal:  Ann Surg       Date:  1967-10       Impact factor: 12.969

9.  Antipseudomonal activity of alpha-sulfoaminopenicillins.

Authors:  K E Price; D R Chisholm; F Leitner; M Misiek; A Gourevitch
Journal:  Appl Microbiol       Date:  1969-06

10.  Carbenicillin resistance in Pseudomonas aeruginosa from clinical material.

Authors:  J H Darrell; P M Waterworth
Journal:  Br Med J       Date:  1969-07-19
View more
  12 in total

1.  Study of the effects of ticarcillin on blood coagulation and platelet function.

Authors:  C H Brown; E A Natelson; M W Bradshaw; P Alfrey C; T W Williams
Journal:  Antimicrob Agents Chemother       Date:  1975-05       Impact factor: 5.191

Review 2.  Newer beta-lactam antibiotics.

Authors:  J M Hamilton-Miller; W Brumfitt
Journal:  Infection       Date:  1974       Impact factor: 3.553

3.  Comparison of ticarcillin and carbenicillin activity against random and select populations Pseudomonas aeruginosa.

Authors:  R B Prior; R J Fass
Journal:  Antimicrob Agents Chemother       Date:  1978-02       Impact factor: 5.191

4.  Activity of carbenicillin and ticarcillin against Pseudomonas aeruginosa compared by paired in vitro tests.

Authors:  K Mai; B Bülow
Journal:  Infection       Date:  1974       Impact factor: 3.553

5.  Morphological alterations of Pseudomonas aeruginosa by ticarcillin: a scanning electron microscope study.

Authors:  R B Prior; J F Warner
Journal:  Antimicrob Agents Chemother       Date:  1974-12       Impact factor: 5.191

6.  BL-P1654, ticarcillin, and carbenicillin: in vitro comparison alone and in combination with gentamicin against Pseudomonas aeruginosa.

Authors:  E R Wald; H C Standiford; B A Tatem; F M Calia; R B Hornick
Journal:  Antimicrob Agents Chemother       Date:  1975-03       Impact factor: 5.191

7.  Comparative activity in vitro of ticarcillin, BL-P1654, and carbenicillin.

Authors:  T C Eickhoff; J M Ehret
Journal:  Antimicrob Agents Chemother       Date:  1976-08       Impact factor: 5.191

Review 8.  Ticarcillin: a review of its pharmacological properties and therapeutic efficacy.

Authors:  R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1980-11       Impact factor: 9.546

9.  Ticarcillin in the treatment of experimental pseudomonas keratitis.

Authors:  A Ahmad; G Smolin; M Okumoto; S Ohno
Journal:  Br J Ophthalmol       Date:  1977-02       Impact factor: 4.638

10.  Clinical pharmacology of ticarcillin (alpha-carboxyl-3-thienylmethyl penicillin, BRL-2288).

Authors:  V Rodriguez; J Inagaki; G P Bodey
Journal:  Antimicrob Agents Chemother       Date:  1973-07       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.